




“Transvaginal radiofrequency ablation myolysis has been recently suggested to be the optimal technique because it is an outpatient, safe, and fast procedure with a rapid recovery, quick return to normal menstruation, major reduction of myoma volume, and correction of anemia.”⁵

VOLUME REDUCTION, SYMPTOM RELIEF



INITIAL ULTRASOUND

Volume: 21.54 cm³
8 total days of bleeding

1-MONTH POST-PROCEDURE

Volume: 8.32 cm³ ↓ 62%
4 total days of bleeding

6-MONTHS POST-PROCEDURE

Volume: 3.83 cm³ ↓ 83%
4 total days of bleeding

STARmed Fibroid RFA Disclaimer

STARmed encourages patients to seek medical attention for typical and atypical symptoms associated with fibroids to help achieve and maintain good health with as high a quality of life as possible. Although many patients may benefit from STARmed Fibroid RFA, this treatment is not for everyone and results may vary. You should talk to your doctor about the potential benefits and risks and whether this treatment is right for you. Information contained in this brochure is not to be used as a substitute for talking to your doctor. You should always talk to your doctor about diagnosis and treatment information. The VIVA combo RF System is cleared by the FDA for use in percutaneous and intraoperative coagulation and ablation of tissue. There is a risk that error may result due to the radiofrequency current on patients who have pacemakers and other active implants. Do not use the radiofrequency generator and electrode on these patients. STARmed Fibroid RFA is generally safe, but complications may occur as a result of the use of the radiofrequency generator and electrode. Risks and complications associated with STARmed Fibroid RFA include, but are not limited to: tumor recurrence, burn due to the overheating of the surgical equipment, dangerous situation due to unskilled equipment control, bleeding of the coagulated part, cross-infection or complications due to the re-use of the inappropriate electrode, ascites/diarrhea, adhesion formation, post-procedural discomfort (cramping, pelvic pain), and transient amenorrhea, injury to adjacent structures, vaginal bleeding and temporary anemia, blood loss requiring transfusion or hysterectomy, pneumothorax, deep vein thrombosis and pulmonary embolus, ventricular fibrillation, treatment failure, and complications related to general anesthesia including death. There is limited data regarding pregnancy following the procedure; if you become pregnant following the procedure, you should contact your doctor immediately. Please consult with your doctor to understand the risks and benefits of surgery and find out if STARmed Fibroid RFA may be right for you. Rx Only.

© 2022 TaeWoong Medical USA. All Rights Reserved. TaeWoong Medical USA and associated logos are trademarks and/or registered trademarks of TaeWoong Medical USA

Reference

1. Turtulici G, Orlandi D, Dedone G, et al. Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system: a preliminary study. *Int J Hyperthermia*. 2019;35(1):97-104. doi:10.1080/02656736.2018.1479778
2. Marsh EE, Al-Hendy A, Kappus D, Galitsky A, Stewart EA, Kerolous M. Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women. *J Womens Health (Larchmt)*. 2018;27(11):1359-1367. doi:10.1089/jwh.2018.7076
3. Plotting the Downward Trend in Traditional Hysterectomy (2018)
4. Fasciani A, Turtulici G, Siri G, Ferrero S, Sirito R. A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas. *Medicina (Kaunas)*. 2020;56(3):122. Published 2020 Mar 12. doi:10.3390/medicina56030122
5. Rey VE, Labrador R, Falcon M, Garcia-Benitez JL. Transvaginal Radiofrequency Ablation of Myomas: Technique, Outcomes, and Complications. *J Laparosc Adv Surg Tech A*. 2019;29(1):24-28. doi:10.1089/lap.2018.0293
6. Santalla-Hernández Á, Naveiro-Fuentes M, Benito-Villena R, López-Criado MS, González-Paredes A, Fernández-Parra J. Efficacy, Complications, and Factors Predictive of Response to Treatment with Transvaginal Radiofrequency Ablation for Symptomatic Uterine Myomas [published online ahead of print, 2022 Jan 26]. *J Minim Invasive Gynecol*. 2022;S1553-4650(22)00039-5. doi:10.1016/j.jmig.2022.01.011



4801 Wilshire Blvd., Suite 280, Los Angeles, CA 90010
E: info@taewoongusa.com T: + 1.323.692.0028 F: + 1.323.692.0038
www.TaeWoongUSA.com



Minimal approach.
Optimal result.

STARmed Fibroid Radiofrequency Ablation

Changing the future of symptomatic fibroid management

www.TaeWoongUSA.com



THE INCISIONLESS, UTERINE SPARING TECHNIQUE THAT WOMEN SEEK

Uterine fibroids are the most common pelvic benign solid tumors in women of reproductive age and the leading benign indicator for hysterectomy¹.

11 million

women in the U.S. are currently diagnosed with fibroids²


25%-50%

women are suffering symptoms secondary to fibroids²

320,000+

hysterectomies are performed for benign indications annually in the U.S.³

Patients are seeking a **less invasive therapy** that possibly **saves the uterus** and can also treat fibroids **without incisions**.⁴



WHY CHOOSE STARmed


- Minimally invasive solution that integrates transvaginal ultrasound (TVUS) guidance and radiofrequency ablation **without incisions**
- **Universal compatibility with nearly all ultrasound systems**, eliminating the need to acquire additional capital
- **Moving-shot technique** and **internal cooling system** to achieve a more complete ablation with minimal tissue charring and re-interventions^{4,5}
- **No minimum size limitations**
- A **portfolio of electrode size selections** with a clear visible electrode tip on TVUS to promote predictable ablation for a range of fibroid sizes

star
RF Electrode
17-35s10F


TRANSCERVICAL ABLATION, TRANSVAGINAL IMAGING

The STARmed Fibroid RFA uses real-time transvaginal ultrasound guidance to locate the fibroid and insert the star RF Electrode into the target fibroid through the cervical canal, causing immediate coagulative necrosis of the fibroid tissue and volume reduction over time.

1. Visualize



2. Target



3. Treat




4. Reduce



THE NON-SURGICAL ALTERNATIVE FOR FIBROID

- Shortest operative time compared to laparoscopic or hysteroscopic approaches⁴
- Ability to treat a higher percentage of myomas (98.6%)⁵
- Reduced median blood loss (20ml vs. 35ml) compared to laparoscopic myomectomy⁵
- Rapid return to normal activities in 1 day⁴
- Rapid return to normal menstruation and hemoglobin level⁵



CLINICALLY PROVEN BENEFITS YOUR PATIENTS SEEK

+ **Improvement in hemoglobin level:**
The mean hemoglobin level improved from 9.3g/dL preoperatively to 11.2g/dL at 3 months⁵

+ **Improvement in quality of life:**
Health Related Quality of Life (UFS-QOL) total score of +38.2% at 30 day follow-up and +44.9% after 12 months⁴

+ **Reduction of myoma size:**
Mean volume reduction of 71% at 12 months follow-up^{4,5}

+ **High patient satisfaction:**
98.04% patients were satisfied with the procedure⁵